Skip to main content
. 2017 Dec 14;92(1):e01070-17. doi: 10.1128/JVI.01070-17

TABLE 4.

Percentages of AVEG 201 adult vaccine recipients with detectable HIV Env-specific IgA

HIV antigen Recipients (%)a
Placebo (n = 10)
Chiron (n = 42)
VaxGen (n = 49)
Visit 2 Visit 11 Visit 2 Visit 11 Visit 2 Visit 11
A1 con gp140 0 0 0 2 0 4
B con gp140 0 0 0 14 2 22
C1 peptide 0 0 0 7 6 6
MN gp120 0 0 0 19 2 8
a

Visit 2 was preimmunization, and visit 11 took place 2 weeks after the last vaccine dose.